Features
Adjustability Reimagined: The LAL+
A look at the newest addition to the LAL family
By NICHOLAS J. BRUNS, OD, FAAO
Aceclidine: the Latest Data from the CLARITY Clinical Trials
Lenz Therapeutics' aceclidine demonstrates positive topline Data in phase 3 trials
By S. BARRY EIDEN, OD, FAAO, Marc Odrich, MD
Deconstructing Advanced Progressive Lens Designs
Understanding advanced progressive lens designs and how to prescribe them for patients’ visual needs.
By Michelle Hoff, OD, FAAO, ABOM, FNAO, Isabel Kazemi, OD, FAAO, Mindi Lewis, MA, ABOC, FNAO, et al.
How to Maintain Consistent Messaging
Maintain Consistent Messaging Across Multiple Locations: A Guide for Eye Care Providers
By Jessilin M. Quint, OD, MBA, MS, FAAO
Multifocal Contact Lenses and Ocular Surface Health
Exploring the physiological implications of presbyopia
By MARK E. SCHAEFFER, OD, Brooke Kaplan, OD
New Full Visual Range IOL Delivers for Patients
Examining the TECNIS Odyssey intraocular lens
Spherical Aberration and the Light Adjustable Lens
How incorporating spherical aberration into the optics of the visual system
By Mitchell P. Weikert, MD
Web Exclusives
Interview: Paul Smith, President and COO of Orasis Pharmaceuticals, discusses Qlosi
Paul Smith, President and COO of Orasis Pharmaceuticals, discusses Qlosi in this interview with Presbyopia Physician co-editors Dr. Jacob R. Lang and Dr. Jennifer Loh.
Departments
News
CooperVision Launches Multifocal Contact Lens
clariti 1 day multifocal 3 Add Contact Lenses are designed to provide optimal visual acuity at all distances.
LENZ Therapeutics Announces $30 Million Investment from Ridgeback Capital
The proceeds will help support the regulatory, pre-commercial and potential commercial launch activities for the company’s lead product candidate, LNZ100 for presbyopia
LENZ Therapeutics Submits NDA for Presbyopia Treatment
LNZ100 is an aceclidine-based ophthalmic solution intended to treat presbyopia.